Phaseline

Targets › SLC6A3

SLC6A3 (Sodium-dependent dopamine transporter): drug programs, companies and trials

48 programs from 44 companies in 100 trials: 38 Phase 2, 29 Phase 4, 19 Phase 3, 14 Phase 1; Psychiatry, Other, Metabolic and endocrine; next expected readout Nov 2026.

Mediates sodium- and chloride-dependent transport of dopamine. Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). (UniProt, Q01959)

Open in Phaseline: the race on SLC6A3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Primus PharmaceuticalsMetaxalone 640 mg
Skeletal muscle relaxant
SLC6A3Phase 4Sciatica Acute; Healthy ParticipantsNov 2026
Rochester Center for Behavioral MedicineDyanavel XR
Amphetamine derivative; CNS stimulant that increases dopamine and norepinephrine release
SLC6A2, SLC6A3Phase 4FatigueDec 2026
Daniel CouryAmphetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent
SLC6A3, SLC6A2Phase 4ADHDJan 2027
Daniel CouryMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4ADHDJan 2027
Matthew J O'Brien, PhD, BCBA-DAmphetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent
SLC6A3, SLC6A2Phase 4Attention Deficit Hyperactivity DisorderMar 2027
Donald Gilbert, MD, MS, FAAN, FAAPMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Attention Deficit Hyperactivity Disorder CombinedMar 2027
VA Office of Research and DevelopmentMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Posttraumatic Stress Disorder (PTSD); EpilepsyMar 2027
Columbia UniversityNaltrexone-Bupropion Combination
Opioid receptor antagonist (naltrexone) combined with norepinephrine-dopamine reuptake inh
OPRM1, SLC6A3Phase 4ObesityJun 2027
Dar Clinical Research Inc.Methylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Attention Deficit Hyperactivity DisorderJul 2027
The Chaim Sheba Medical Centermethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Velocardiofacial SyndromeAug 2027
Axsome TherapeuticsBupropion (AXS-05)
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Major Depressive Disorder; Smoking Cessation; Major Depressive Disorder (MDD); Cigarette Smoking-Related Carcinoma …Dec 2027
Johns Hopkins UniversityMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4ADHD - Combined TypeNov 2028
Currax PharmaceuticalsBupropion
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4ObesityJan 2029
Gagan JoshiAmphetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent
SLC6A3, SLC6A2Phase 4Attention Deficit Hyperactivity Disorder (ADHD)Feb 2030
Children's Hospital Medical Center, CincinnatiMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Attention-Deficit/Hyperactivity Disorder (ADHD)Feb 2030
Hospital de Clinicas de Porto AlegreMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Attention Deficit Disorder With HyperactivityDec 2032
The Royal's Institute of Mental Health ResearchContrave
Naltrexone/Bupropion combination; naltrexone is a mu-opioid receptor antagonist and buprop
OPRM1, SLC6A2, SLC6A3Phase 4Obesity–
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityFlupentixol-Melitracen
Antipsychotic-antidepressant combination; flupentixol is a dopamine antagonist, melitracen
DRD2, SLC6A3Phase 4Thyroid-Associated Ophthalmopathy–
NYU Langone HealthMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Attention-deficit/Hyperactivity Disorder–
Florida International UniversityMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4ADHD–
Iuliu Hatieganu University of Medicine and PharmacyNefopam
Non-opioid analgesic; mechanism includes monoamine reuptake inhibition and NMDA receptor a
SLC6A2, SLC6A3, GRIN1Phase 4Pancreatoduodenectomy–
Axsome TherapeuticsSolriamfetol Dose A
Dopamine and norepinephrine reuptake inhibitor
SLC6A3, SLC6A2Phase 3Excessive Sleepiness; Binge-Eating Disorder; ADHD; Major Depressive Disorder With Excessive Daytime Sleepiness SymptomsDec 2026
M.D. Anderson Cancer CenterMethylphenidate Hydrochloride
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 3Advanced Malignant Neoplasm; Sleep; Prostate Cancer; Prostate Carcinoma …Dec 2026
University Hospital, Strasbourg, FranceMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 3Adult ADHDMay 2027
OtsukaCentanafadine (EB-1020)
Monoamine transporter inhibitor
SLC6A4, SLC6A3, SLC6A2Phase 3Attention-Deficit Hyperactivity Disorder(ADHD); Attention Deficit Hyperactivity Disorder (ADHD)Aug 2027
Odense University HospitalMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 3Brain Tumor, PediatricDec 2029
Vrije Universiteit BrusselMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 3Fatigue–
University of Haifamethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 2Posttraumatic Stress Disorder; PTSDDec 2026
RemedyMidomafetamine
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 2Post Traumatic Stress DisorderMar 2027
Definium Therapeutics USMidomafetamine (DT402)
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 2Autism Spectrum DisorderAug 2027
Institut National de la Santé Et de la Recherche Médicale, France18F-LBT-999
Dopamine transporter (DAT) PET imaging agent
SLC6A3Phase 2Coma, TraumaticSep 2027
Sunnybrook Health Sciences CentreMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 2Alzheimer s DiseaseOct 2027
Medical University of LodzLisdexamfetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor
SLC6A3, SLC6A2, SLC18A2Phase 2Attention Deficit Disorder with HyperactivityDec 2027
Medical University of LodzMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 2Attention Deficit Disorder with HyperactivityDec 2027
Centre hospitalier de l'Université de Montréal (CHUM)Lisdexamfetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor
SLC6A3, SLC6A2, SLC18A2Phase 2Methamphetamine AbuseDec 2027
University of RochesterMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 2Chronic PainDec 2027
Prof. Dr. Frank BehrensDEX IR tablets
Sympathomimetic amine; inhibits reuptake of dopamine and noradrenaline; increases monoamin
SLC6A3, SLC6A2Phase 2Attention-Deficit/Hyperactivity Disorder (ADHD)Mar 2028
Prof. Dr. Frank BehrensDEX XL
Sympathomimetic amine; inhibits reuptake of dopamine and noradrenaline; increases monoamin
SLC6A3, SLC6A2Phase 2Attention-Deficit/Hyperactivity Disorder (ADHD)Mar 2028
GradalisModafinil
Dopamine transporter inhibitor
SLC6A3Phase 2Ovarian Cancer; Sleep Deprivation; Attention - no Condition is Being Assessed - Healthy Adults; Cognition …Dec 2028
Parnassia Addiction Research CentreSustained-release Dexamphetamine
Dopamine reuptake inhibitor
SLC6A3Phase 2Cocaine Use DisorderJan 2029
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)18F-DOPA
Dopamine transporter imaging agent for neuroendocrine tumors
SLC6A3Phase 2ACTHDec 2030
AlgoTherapeutixATX01 10%
Amitriptyline hydrochloride topical formulation; tricyclic antidepressant with analgesic p
SLC6A4, SLC6A3Phase 2Chemotherapy-induced Peripheral Neuropathy–
CSPC ZhongQi Pharmaceutical TechnologyAmmoxetine hydrochloride Enteric-coated Tablets (new formulation)
norepinephrine-dopamine reuptake inhibitor
SLC6A3Phase 1Healthy ParticipantsNov 2026
Resilient PharmaceuticalsMidomafetamine
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 1Healthy Volunteers; Post-Traumatic Stress Disorder; PTSD, Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder …Feb 2027
St. Jude Children's Research HospitalMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 1Sickle Cell DiseaseJul 2027
Rachel YehudaMDMA Hydrochloride
Serotonin-norepinephrine-dopamine releasing agent; promotes prosocial behavior and emotion
SLC6A4, SLC6A2, SLC6A3Phase 1Mental WellbeingSep 2029
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)[18F]-DOPA
Fluorine-18 labeled L-DOPA for neuroendocrine tumor imaging via amino acid uptake and deca
SLC6A3Phase 1PheochromocytomaNov 2048
Massachusetts General HospitalMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 1Brain Injury Traumatic Severe (Diagnosis)–

Conditions

Post Traumatic Stress Disorder (6) Healthy Participants (5) ADHD (5) Obesity (3) Attention Deficit Hyperactivity Disorder (ADHD) (3) Posttraumatic Stress Disorder (3) Attention-Deficit/Hyperactivity Disorder (ADHD) (3) Schizophrenia (3) Attention Deficit Hyperactivity Disorder (2) Attention-Deficit Hyperactivity Disorder(ADHD) (2) PTSD (2) Attention Deficit Disorder with Hyperactivity (2)

Modalities

small molecule (39), protein or peptide (6), mixed (2), antibody (1)

Companies

Axsome Therapeutics (2) Medical University of Lodz (2) Daniel Coury (2) Prof. Dr. Frank Behrens (2) Columbia University (1) CSPC ZhongQi Pharmaceutical Technology (1) Johns Hopkins University (1) Rachel Yehuda (1) NYU Langone Health (1) Donald Gilbert, MD, MS, FAAN, FAAP (1) Iuliu Hatieganu University of Medicine and Pharmacy (1) The Chaim Sheba Medical Center (1) University of Rochester (1) Dar Clinical Research Inc. (1) M.D. Anderson Cancer Center (1) Currax Pharmaceuticals (1) Otsuka (1) Primus Pharmaceuticals (1) VA Office of Research and Development (1) University of Haifa (1)

Related targets

SLC6A2 (38) SLC6A4 (6) OPRM1 (2) SLC18A2 (2) GRIN1 (1) DRD2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.